uniQure announced striking 36-month clinical data from its Phase I/II AMT-130 gene therapy trial for Huntington’s disease, reporting a 75% slowdown in disease progression at high dose among patients. The composite Unified Huntington’s Disease Rating Scale (cUHDRS) primary endpoint was met with significant effects also found in secondary measures like total functional capacity. University College London's Dr. Sarah Tabrizi hailed the data as a major advance offering hope to patients and families. uniQure plans a 2026 FDA Biologics License Application submission with U.S. launch expected the same year. Investors pushed the stock to a five-year high following the news.